Treatment Delays With CAR-T Therapy: A High Price to Pay
A treatment delay of 6 months was found to result in up to a 67.3% loss in social value for patients receiving chimeric antigen receptor T-cell therapy.
John Schieszer
Contributing Writer https://www.hematologyadvisor.com
John Schieszer is an award winning medical journalist who produces The Medical Minute podcasts. John received his BA in journalism from the University of Missouri-Columbia School of Journalism and his MA in english from the University of Missouri-St. Louis. In 1990, John was awarded the Case Western Reserve University School of Medicine’s Third Annual Fellowship for Journalists in Biomedical Research. In 1992, he completed a Medical Fellowship at the Marine Biological Laboratories in Woods Hole, Massachusetts.
